Wedbush Reiterates Neutral on Vera Therapeutics, Maintains $35 Price Target

Vera Therapeutics, Inc. Class A

Vera Therapeutics, Inc. Class A

VERA

0.00

Wedbush analyst Laura Chico reiterates Vera Therapeutics (NASDAQ: VERA) with a Neutral and maintains $35 price target.